Stock Information
Stock Quote
| (Common Stock) | |
|---|---|
| (US Dollars) | |
| Change | |
| Exchange (%) | (US Dollar) |
| Intraday High | |
| Intraday Low | |
| Volume | |
| Today's Open | |
| Previous Close | |
| 52 Week High | |
| 52 Week Low | |
| Data as of | |
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Investor Relations Contacts
Sarah Cavanaugh
Senior Vice President
Corporate Affairs and Administration
Patrick Till
Senior Director
Investor Relations & Corporate Communications
More →
About us
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
Our Pipeline
© 2021 Celldex Therapeutics, All rights reserved | Site Map | Privacy Policy | Terms of Use | Contact